We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Amarin Appoints Medpace as CRO for two Phase 3 Cardiovascular Trials

News   Oct 20, 2009

 
Amarin Appoints Medpace as CRO for two Phase 3 Cardiovascular Trials
 
 
 

RELATED ARTICLES

"Good" Cholesterol Likened to "Velcro Ball"

News

Researchers report on an underappreciated part of high-density lipoprotein (HDL): not its lipids, but its proteins. They showed that a complex mix of genetic and environmental factors contribute to the protein makeup of HDL particles.

READ MORE

Endocrine-disrupting Chemicals Linked to Equine Metabolic Syndrome

News

Endocrine-disrupting chemicals (EDCs) in a horse's environment may play a role in the development of equine metabolic syndrome (EMS).

READ MORE

Antidepressant Based on Ketamine Gets Backing from FDA Advisory Group

News

A form of the hallucinogenic party drug ketamine has cleared one of the final hurdles toward clinical use as an antidepressant. During a meeting at the US Food and Drug Administration (FDA) in Silver Spring, Maryland, an independent advisory panel voted 14-2 in favor of recommending a compound known as esketamine for use in treating depression.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE